ArticleJournal of asthma and allergy2026

Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study.

Mirna Vergles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.